LP
PBMWW

LMR Partners’s Psyence Biomedical Warrant PBMWW Stock Holding History

LMR Partners’s Portfolio PBMWW Stock Details PBMWW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-200,000
Closed -$2.52K – 1657
2024
Q3 		$2.52K Buy
+200,000
New +$3.5K ﹤0.01% 1202

Other funds holding PBMWW

HCI
Harraden Circle Investments New York $499M AUM 24.03% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $28.2B AUM 21.78% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

LMR Partners's PBMWW Position: Q1 2026 in Review

LMR Partners held its Psyence Biomedical Warrant (PBMWW) position steady in Q1 2026 at 200,000 shares worth $3.64K. The position accounts for ﹤0.01% of the portfolio, ranked #1393.

LMR Partners first reported a position in PBMWW in Q1 2024 and has held it in 8 quarters since. The position peaked at $14K in Q1 2024. 19 funds tracked by Wall St. Rank hold PBMWW as of Q1 2026.

  • LMR Partners held 200,000 shares of Psyence Biomedical Warrant worth $3.64K as of Q1 2026.
  • LMR Partners left its Psyence Biomedical Warrant share count unchanged in Q1 2026.
  • Psyence Biomedical Warrant made up ﹤0.01% of LMR Partners's portfolio in Q1 2026, its #1393 holding.
  • LMR Partners first reported a position in Psyence Biomedical Warrant in Q1 2024 and has held it in 8 quarters since.
  • LMR Partners's Psyence Biomedical Warrant position peaked at $14K in Q1 2024.
  • 19 funds tracked by Wall St. Rank held Psyence Biomedical Warrant as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.